Skip to main content

Advertisement

SpringerLink
Log in

Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma

  • Original Article
  • Published:
Tumor Biology

Abstract

The oncogenic transcription factor signal transducer and activator of transcription 3 (STAT3) is a cytokine-activated transcription factor controlling inflammation, cell proliferation, survival, and differentiation in normal tissue as well as in tumor growth. One of its most important negative regulators is the suppressor of cytokine signaling 3 (SOCS3). Here, we analyzed SOCS3 and other tumor-associated local immune regulators in human clear cell renal cell carcinoma (ccRCC). Analyses were performed in tumor and adjacent tumor-free healthy renal tissue from 35 patients with ccRCC. For functional analysis, ccRCC Caki-1 cell lines were stimulated with IL-6 and IFNγ in cell culture assays. We observed significantly lower SOCS3 messenger RNA (mRNA) levels in tumor tissue compared to healthy tissue. SOCS3 mRNA strongly correlated within tumor and healthy tissue. Interestingly vice versa, SOCS3 protein levels were significantly higher in tumor tissue than in healthy tissue. IL-22 and IL-22R1 mRNA displayed no differences in tumor and healthy tissue. Stimulation of Caki-1 cells with IFNγ resulted in markedly increased SOCS3 mRNA levels. We conclude that SOCS3 along with STAT3 participates in regulatory mechanisms in ccRCC, which certainly features only one of multiple factors involved but nevertheless merits further attention.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2
Fig. 3
Fig. 4

Similar content being viewed by others

References

  1. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in globocan 2012. Int J Cancer. 2015;136:E359–386.

    Article  CAS  PubMed  Google Scholar 

  2. Patard JJ, Leray E, Rioux-Leclercq N, Cindolo L, Ficarra V, Zisman A, et al. Prognostic value of histologic subtypes in renal cell carcinoma: a multicenter experience. J Clin Oncol. 2005;23:2763–71.

    Article  PubMed  Google Scholar 

  3. Koebel CM, Vermi W, Swann JB, Zerafa N, Rodig SJ, Old LJ, et al. Adaptive immunity maintains occult cancer in an equilibrium state. Nature. 2007;450:903–7.

    Article  CAS  PubMed  Google Scholar 

  4. Elinav E, Nowarski R, Thaiss CA, Hu B, Jin C, Flavell RA. Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer. 2013;13:759–71.

    Article  CAS  PubMed  Google Scholar 

  5. Eto M, Kamba T, Miyake H, Fujisawa M, Kamai T, Uemura H, et al. Japan Immunotherapy S-SGfKC: Stat3 polymorphism can predict the response to interferon-alpha therapy in patients with metastatic renal cell carcinoma. Eur Urol. 2013;63:745–52.

    Article  CAS  PubMed  Google Scholar 

  6. Horiguchi A, Asano T, Kuroda K, Sato A, Asakuma J, Ito K, et al. Stat3 inhibitor wp1066 as a novel therapeutic agent for renal cell carcinoma. Br J Cancer. 2010;102:1592–9.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  7. Horiguchi A, Oya M, Shimada T, Uchida A, Marumo K, Murai M. Activation of signal transducer and activator of transcription 3 in renal cell carcinoma: a study of incidence and its association with pathological features and clinical outcome. J Urol. 2002;168:762–5.

    Article  CAS  PubMed  Google Scholar 

  8. Darnell Jr JE. Stats and gene regulation. Science. 1997;277:1630–5.

    Article  CAS  PubMed  Google Scholar 

  9. Yoshimura A, Naka T, Kubo M. Socs proteins, cytokine signalling and immune regulation. Nat Rev Immunol. 2007;7:454–65.

    Article  CAS  PubMed  Google Scholar 

  10. Yamamoto K, Yamaguchi M, Miyasaka N, Miura O. Socs-3 inhibits il-12-induced stat4 activation by binding through its sh2 domain to the stat4 docking site in the il-12 receptor beta2 subunit. Biochem Biophys Res Commun. 2003;310:1188–93.

    Article  CAS  PubMed  Google Scholar 

  11. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, et al. Cis3/socs3/ssi3 plays a negative regulatory role in stat3 activation and intestinal inflammation. J Exp Med. 2001;193:471–81.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  12. Shouda T, Yoshida T, Hanada T, Wakioka T, Oishi M, Miyoshi K, et al. Induction of the cytokine signal regulator socs3/cis3 as a therapeutic strategy for treating inflammatory arthritis. J Clin Invest. 2001;108:1781–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  13. Gomez-Guerrero C, Lopez-Franco O, Sanjuan G, Hernandez-Vargas P, Suzuki Y, Ortiz-Munoz G, et al. Suppressors of cytokine signaling regulate fc receptor signaling and cell activation during immune renal injury. J Immunol. 2004;172:6969–77.

    Article  CAS  PubMed  Google Scholar 

  14. He B, You L, Uematsu K, Zang K, Xu Z, Lee AY, et al. Socs-3 is frequently silenced by hypermethylation and suppresses cell growth in human lung cancer. Proc Natl Acad Sci U S A. 2003;100:14133–8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Li G, Xu J, Wang Z, Yuan Y, Li Y, Cai S, He Y: Low expression of socs-1 and socs-3 is a poor prognostic indicator for gastric cancer patients. J Cancer Res Clin Oncol 2014.

  16. Ogata H, Kobayashi T, Chinen T, Takaki H, Sanada T, Minoda Y, et al. Deletion of the socs3 gene in liver parenchymal cells promotes hepatitis-induced hepatocarcinogenesis. Gastroenterology. 2006;131:179–93.

    Article  CAS  PubMed  Google Scholar 

  17. Stofas A, Levidou G, Piperi C, Adamopoulos C, Dalagiorgou G, Bamias A, et al. The role of cxc-chemokine receptor cxcr2 and suppressor of cytokine signaling-3 (socs-3) in renal cell carcinoma. BMC Cancer. 2014;14:149.

    Article  PubMed  PubMed Central  Google Scholar 

  18. Erdogan F, Demirel A, Polat O. Prognostic significance of morphologic parameters in renal cell carcinoma. Int J Clin Pract. 2004;58:333–6.

    Article  CAS  PubMed  Google Scholar 

  19. Sandlund J, Oosterwijk E, Grankvist K, Oosterwijk-Wakka J, Ljungberg B, Rasmuson T. Prognostic impact of carbonic anhydrase ix expression in human renal cell carcinoma. BJU Int. 2007;100:556–60.

    Article  PubMed  Google Scholar 

  20. Walther MM, Johnson B, Culley D, Shah R, Weber J, Venzon D, et al. Serum interleukin-6 levels in metastatic renal cell carcinoma before treatment with interleukin-2 correlates with paraneoplastic syndromes but not patient survival. J Urol. 1998;159:718–22.

    Article  CAS  PubMed  Google Scholar 

  21. Starr R, Willson TA, Viney EM, Murray LJ, Rayner JR, Jenkins BJ, et al. A family of cytokine-inducible inhibitors of signalling. Nature. 1997;387:917–21.

    Article  CAS  PubMed  Google Scholar 

  22. Hoegl S, Bachmann M, Scheiermann P, Goren I, Hofstetter C, Pfeilschifter J, et al. Protective properties of inhaled il-22 in a model of ventilator-induced lung injury. Am J Respir Cell Mol Biol. 2011;44:369–76.

    Article  CAS  PubMed  Google Scholar 

  23. Horiguchi A, Oya M, Marumo K, Murai M. Stat3, but not erks, mediates the il-6-induced proliferation of renal cancer cells, achn and 769p. Kidney Int. 2002;61:926–38.

    Article  CAS  PubMed  Google Scholar 

  24. Yu H, Pardoll D, Jove R. Stats in cancer inflammation and immunity: a leading role for stat3. Nat Rev Cancer. 2009;9:798–809.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Si H, Banga RS, Kapitsinou P, Ramaiah M, Lawrence J, Kambhampati G, et al. Human and murine kidneys show gender- and species-specific gene expression differences in response to injury. PLoS ONE. 2009;4:e4802.

    Article  PubMed  PubMed Central  Google Scholar 

  26. Neuwirt H, Eder IE, Puhr M, Rudnicki M. Socs-3 is downregulated in progressive ckd patients and regulates proliferation in human renal proximal tubule cells in a stat1/3 independent manner. Lab Investig. 2013;93:123–34.

    Article  CAS  PubMed  Google Scholar 

  27. Thoenes W, Storkel S, Rumpelt HJ. Histopathology and classification of renal cell tumors (adenomas, oncocytomas and carcinomas). The basic cytological and histopathological elements and their use for diagnostics. Pathol Res Pract. 1986;181:125–43.

    Article  CAS  PubMed  Google Scholar 

  28. Guo C, Yang G, Khun K, Kong X, Levy D, Lee P, et al. Activation of stat3 in renal tumors. Am J Transl Res. 2009;1:283–90.

    CAS  PubMed  PubMed Central  Google Scholar 

  29. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143–64.

    Article  CAS  PubMed  Google Scholar 

  30. Wolk K, Sabat R. Interleukin-22: a novel t- and nk-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006;17:367–80.

    Article  CAS  PubMed  Google Scholar 

  31. Wolk K, Kunz S, Witte E, Friedrich M, Asadullah K, Sabat R. Il-22 increases the innate immunity of tissues. Immunity. 2004;21:241–54.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgments

We especially thank Ecatarina Oplesch for her technical support.

Author information

Authors and Affiliations

  1. Department of Urology and Pediatric Urology, University Hospital of the Philipps-University Marburg, Baldinger Strasse, Marburg, Germany

    Anja Urbschat, Svenja Stumpf, Jörg Hänze, Rainer Hofmann & Axel Hegele

  2. Department of Anesthesiology and Operative Intensive Care Medicine, Kepler University Hospital Linz, Linz, Austria

    Patrick Paulus

  3. Department of Biomedicine, Aarhus University, Aarhus, Denmark

    Thorsten J. Maier

  4. Clinic of Urology and Andrology, Landeskrankenhaus Hall in Tirol, Hall, Austria

    Christine Weipert

Authors
  1. Anja Urbschat
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Svenja Stumpf
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Jörg Hänze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Patrick Paulus
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Thorsten J. Maier
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Christine Weipert
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Rainer Hofmann
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Axel Hegele
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Anja Urbschat.

Ethics declarations

Conflicts of interest

None

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Funding

This study was financially supported by a junior researchers grant to A.U. (Fokus Programm, Förderlinie A from the Goethe-University Frankfurt) and by the German Research Foundation (DFG projects MA-5825/1-1) to T.J.M. The founders of the study had no role in design, interpretation of the data, nor in the decision to publish.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Urbschat, A., Stumpf, S., Hänze, J. et al. Expression of the anti-inflammatory suppressor of cytokine signaling 3 (SOCS3) in human clear cell renal cell carcinoma. Tumor Biol. 37, 9649–9656 (2016). https://doi.org/10.1007/s13277-016-4857-9

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13277-016-4857-9

Keywords

Search

Navigation